Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07132801
NA

Comparison of Two Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels

Sponsor: Qualia Life Sciences

View on ClinicalTrials.gov

Summary

This is a randomized, double-blind, placebo-controlled, parallel-group study evaluating the effects of two distinct Qualia NAD⁺ formulations on intracellular NAD⁺ levels in healthy adults aged 35-75 years. Approximately 180 participants will be randomized to one of three study arms: Qualia NAD⁺ version 1, Qualia NAD⁺ version 2, or placebo. Each participant will take two capsules of their assigned product once daily in the morning, with or without food, over a 28-day period. The primary outcome is the change in intracellular NAD⁺ levels, assessed via at-home finger-stick blood collection at baseline and study completion. Secondary endpoints include changes in aging-related symptoms (AMFS scores), health-related quality of life (RAND SF-36), and evaluation of safety and tolerability. All assessments, including electronic questionnaires, are completed remotely without in-person visits.

Official title: Comparison of Two Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels: A Randomized, Double-Blind, Placebo-Controlled Three-Arm Trial

Key Details

Gender

All

Age Range

35 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

180

Start Date

2025-10-13

Completion Date

2025-12-15

Last Updated

2025-08-20

Healthy Volunteers

Yes

Interventions

DIETARY_SUPPLEMENT

Qualia NAD⁺ version 1

Qualia NAD+ version 1 manufactured by Qualia Life Sciences

DIETARY_SUPPLEMENT

Qualia NAD⁺ version 2

Qualia NAD+ version 2 manufactured by Qualia Life Sciences

DIETARY_SUPPLEMENT

Placebo

Rice Flour

Locations (1)

Qualia Life Sciences

Carlsbad, California, United States